Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

DeepNPA: A protBert-based framework for residue-level annotation of neuropeptide precursors.

Created on 12 Oct 2026

Authors

Xin-Yu Li, Yang Yu, Li-Ping Liu, Meng-Ze Du, Qiang Tang, Juan-Juan Kang

Published in

iScience. Volume 29. Issue 10. Pages 117680. Oct 16, 2026. Epub Sep 29, 2026.

Abstract

Neuropeptides are key signaling molecules that regulate the nervous and endocrine systems, and their maturation depends on precise proteolytic cleavage of precursor proteins. However, residue-level annotation remains essential yet experimentally labor intensive, with limited dedicated computational tools. Here, we present DeepNPA, a residue-level annotation framework that integrates ProtBert, a pretrained protein language model, with focal loss for imbalance-aware optimization. DeepNPA was trained and evaluated on a non-redundant Swiss-Prot-derived dataset annotated using the BIO scheme. On a held-out test dataset, DeepNPA achieved strong performance, with an accuracy of 0.953, an F1-score of 0.927, and an AUPRC of 0.965. On an independent benchmark dataset, DeepNPA outperformed NeuroCS and NeuroPred, achieving an ACC of 0.969 and Matthews correlation coefficient (MCC) of 0.666. External validation further demonstrated its ability to identify neuropeptide regions and their associated cleavage sites. In addition, we provided an online prediction platform to facilitate neuropeptide precursor annotation and cleavage site analysis.

PMID:
42861395
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement